The aim of the current study was to report the safety and efficacy of a fixed-dose regimen in an all-comer population of patients with R/M HNSCC, regardless of PD-L1 or HPV status, from a larger HNSCC expansion cohort of the KEYNOTE-012 trial. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.